Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report issued on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on MRNS. Truist Financial cut shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. TD Cowen reiterated a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Cantor Fitzgerald restated an “overweight” rating and set a $4.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. HC Wainwright reissued a “neutral” rating and set a $2.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Finally, Royal Bank of Canada dropped their price objective on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Stock Down 0.5 %

Shares of MRNS stock opened at $0.54 on Wednesday. Marinus Pharmaceuticals has a twelve month low of $0.22 and a twelve month high of $10.50. The business has a fifty day simple moving average of $0.40 and a 200 day simple moving average of $0.95. The company has a market cap of $29.85 million, a P/E ratio of -0.22 and a beta of 1.03.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Point72 DIFC Ltd acquired a new stake in Marinus Pharmaceuticals during the 2nd quarter worth about $28,000. AQR Capital Management LLC boosted its position in shares of Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Marinus Pharmaceuticals in the second quarter worth approximately $64,000. World Investment Advisors LLC acquired a new position in Marinus Pharmaceuticals in the third quarter valued at approximately $104,000. Finally, Deltec Asset Management LLC bought a new position in shares of Marinus Pharmaceuticals during the 4th quarter worth approximately $107,000. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.